[Study on the cost-effectiveness of therapeutic scheme of acute bacillary dysentery].
A prospective study on the casts of acute bacillary dysentery treatment with antibiotics of aminoglycoside and the 3rd generation of cephalosporin, along with drug sensitive test in vitro was carried out. The results showed that the clinical therapeutic effects and the sensitive rates to drug in vitro between the two kinds of antibiotics were not statistically different (P > 0.05), but the costs of treatment with these two methods were significantly different. The therapeutic costs were calculated in Ren Ming Bi per day per kilogram body weight. The average therapeutic cost with the 3rd generation of cephalosporin was 44.85 times as that with aminoglycoside. The highest cost by Fortum was 364 times Higher than by Gentamycin. Through cost analysis, conclusion was drawn that the 3rd generation of cephalosporin should not be taken as first choice to treat a acute bacillary dysentery.
D000293:Adolescent; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D002511:Cephalosporins / Q000191:economics* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D004405:Dysentery, Bacillary / Q000188:drug therapy / Q000191:economics*; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies